SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a private exchange of $1.4 billion in convertible senior notes for common stock, a move that community members are debating as either a strategic balance sheet improvement or further dilutive pressure on shareholders. The conversation remains highly polarized, with active discussions focused on whether this debt-for-equity swap is a precursor to a potential acquisition, such as an eBay merger, or a sign of continued lack of value creation for retail investors.

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending due to intense market anticipation surrounding its upcoming first public earnings report and a major insider share unlock scheduled for this week, which has triggered heavy short-selling activity. The community is sharply divided, with bulls viewing the current price weakness as a long-term entry opportunity while bears express concerns over high valuations, insider sell-offs, and the company's capital-intensive business model.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is gaining momentum as investors weigh strong commercial performance from its MS franchise against potential pipeline expansions into myasthenia gravis and schizophrenia. The community is heavily focused on the company's trajectory toward reaching annual revenue milestones, with many viewing the stock as a prime acquisition target due to its best-in-class assets and the recent sector-wide trend of significant buyout premiums.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending following a strong quarterly earnings report that beat expectations on both revenue and earnings per share, fueled by record-high customer counts and continued store expansion. The community is actively discussing the stock's potential for a U.S. relisting, the impact of normalizing delivery costs on profit margins, and the company's aggressive strategy to maintain market share despite increased sector competition.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is experiencing extreme volatility as investors weigh the stock's robust AI-driven memory demand and favorable fundamentals against broader market sell-offs and geopolitical fears regarding Chinese competition. While the community remains deeply divided between those holding long-term for a structural AI memory supercycle and those fearing a cyclical peak, active discussions are fixated on whether current price action reflects genuine fundamental weakness or deliberate market manipulation.

Bristol Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers small molecules, products produced from biological processes called biologics, and chimeric antigen receptor (CAR-T) cell therapies. The company was founded in August 1933 and is headquartered in Princeton, NJ.

Bristol-Myers Squibb Co.

Bristol-Myers Squibb is trending following the company's Q4 earnings beat and optimistic 2026 revenue guidance, which have reassured investors regarding its growth portfolio's ability to counter legacy drug patent cliffs. Community discussion is heavily focused on the stock's stability as a defensive dividend play and its ongoing pipeline developments, particularly the recent expansion of its CELMoD program.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca's stock is under pressure following reports of a potential $400 billion merger with Bristol Myers Squibb, an industry-shaking tie-up that has sparked intense debate over potential oncology synergies and regulatory antitrust hurdles. Community members are actively weighing the strategic logic of such massive pharmaceutical consolidation against concerns about regulatory approval and integration risks.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is rallying as investors look past short-term volatility and sector-wide sell-offs, betting that the company's expanding AI accelerator demand and strong enterprise partnerships will drive sustained growth. The community remains focused on upcoming earnings, with active debate centered on whether recent price action is a fundamental recovery or a temporary technical rebound.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is capturing significant attention as investors position themselves ahead of the upcoming quarterly earnings report, with the community actively debating whether the company's AI-driven growth and enterprise adoption can justify its current market valuation. Discussions are heavily focused on the high-stakes nature of this catalyst, with bulls emphasizing rapid expansion in commercial revenue and government contracts, while bears raise concerns about the stock's premium valuation and the sustainability of its recent growth trajectory.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The Dow is trending as investors weigh geopolitical tensions in the Middle East against ongoing corporate earnings reports. Community sentiment is deeply divided, with many actively debating the impact of government policies and inflation on the broader economy while reacting to speculative headlines regarding international relations.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Compugen Reports Second Quarter 2026 Results

Compugen Reports Second Quarter 2026 Results Compugen Reports Second Quarter 2026 Results PR Newswire HOLON, Israel, Aug. 3, 2026 COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the interim analysis expected by Q1 2027Trial-in-progress poster on...

Compugen to Participate in BTIG Biotechnology Conference 2026

Compugen to Participate in BTIG Biotechnology Conference 2026 Compugen to Participate in BTIG Biotechnology Conference 2026 PR Newswire HOLON, Israel, July 21, 2026 HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company...

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026

Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 Compugen to Release Second Quarter 2026 Results on Monday, August 3, 2026 PR Newswire HOLON, Israel, July 20, 2026 HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage...

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress

Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress PR Newswire HOLON, Israel, June 18, 2026...

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 Compugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026 PR Newswire HOLON, Israel, June 11, 2026 HOLON, Israel, June 11, 2026...

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development

Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development Compugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development PR Newswire HOLON, Israel, June 8, 2026 HOLON, Israel, June 8, 2026 /PRNewswire...

Compugen Q1 2026 Earnings Call: Complete Transcript

Compugen Q1 Earnings Call Highlights

Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates

Compugen (CGEN) delivered earnings and revenue surprises of -9.14% and -16.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Compugen Reports First Quarter 2026 Results

Compugen Reports First Quarter 2026 Results Compugen Reports First Quarter 2026 Results PR Newswire HOLON, Israel, May 18, 2026 COM701 MAIA-ovarian trial actively enrolling patients across all...

$CGEN Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.07 up 12.50% YoY
• Reported revenue of $2.6M up 107.00% YoY

Stocktwits

Compugen Ltd

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.07 up 12.50% YoY
• Reported revenue of $2.6M up 107.00% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

$CGEN Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.08
• Reported revenue of $2.18M down -4.73% YoY
• Compugen expects its solid financial position with cash runway to fund operations into 2029, enabling advancement of its differentiated immuno-oncology pipeline and leveraging its AI/ML platform.

CGEN  Earnings Call

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

CGENCompugen Ltd

Fundamentals

Connect Stocktwits to ChatGPT

Latest CGEN News